Related references
Note: Only part of the references are listed.Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings
Chiara Demartini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm
Daniele Martinelli et al.
CEPHALALGIA (2022)
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates
Lars Jacob Stovner et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study
Alicia Gonzalez-Martinez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2022)
Multimodal machine learning in precision health: A scoping review
Adrienne Kline et al.
NPJ DIGITAL MEDICINE (2022)
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
Jason C. Ray et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives
Tiffani J. Mungoven et al.
FRONTIERS IN PAIN RESEARCH (2021)
Are machine learning approaches the future to study patients with migraine?
Maria A. Rocca et al.
NEUROLOGY (2020)
Chronic migraine and Botulinum Toxin Type A: Where do paths cross?
Daniele Martinelli et al.
TOXICON (2020)
What We Gain From Machine Learning Studies in Headache Patients
Roberta Messina et al.
FRONTIERS IN NEUROLOGY (2020)
A Machine Learning Approach for the Differential Diagnosis of Alzheimer and Vascular Dementia Fed by MRI Selected Features
Gloria Castellazzi et al.
FRONTIERS IN NEUROINFORMATICS (2020)
Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
Ozan E. Eren et al.
SCIENTIFIC REPORTS (2020)
Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine
Clara Dominguez Vivero et al.
TOXINS (2020)
Machine learning approach to predict medication overuse in migraine patients
Patrizia Ferroni et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment
Francesca Schiano di Cola et al.
FRONTIERS IN NEUROLOGY (2019)
Artificial Intelligence Transforms the Future of Health Care
Nariman Noorbakhsh-Sabet et al.
AMERICAN JOURNAL OF MEDICINE (2019)
Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study
Marina de Tommaso et al.
EUROPEAN NEUROLOGY (2019)
Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
Franklin Parrales Bravo et al.
HELIYON (2019)
CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study
Clara Dominguez et al.
HEADACHE (2018)
May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?
Carlo Lovati et al.
NEUROLOGICAL SCIENCES (2018)
When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month
M. Torres-Ferrus et al.
CEPHALALGIA (2017)
Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design
Daniel Serrano et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine
Paola Sarchielli et al.
FRONTIERS IN NEUROLOGY (2017)
Automatic migraine classification via feature selection committee and machine learning techniques over imaging and questionnaire data
Yolanda Garcia-Chimeno et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2017)
Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal
Catherine S. Hubbard et al.
FRONTIERS IN HUMAN NEUROSCIENCE (2016)
OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
Eva Cernuda-Morollon et al.
PAIN (2015)
Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study
Kuan-Hsiang Lin et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2014)
Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B
Patrick M. Grogan et al.
HEADACHE (2013)
12 item Allodynia Symptom Checklist/Brasil: cross-cultural adaptation, internal consistency and reproducibility
Lidiane Lima Florencio et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2012)
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Min Yang et al.
CEPHALALGIA (2011)
Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study
Giorgio Sandrini et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Predicting Migraine Responsiveness to Botulinum Toxin Type A Injections
Christine C. Kim et al.
ARCHIVES OF DERMATOLOGY (2010)
Tracing transformation Chronic migraine classification, progression, and epidemiology
Richard B. Lipton
NEUROLOGY (2009)
Migraine prophylaxis with botulinum toxin A is associated with perception of headache
Rami Burstein et al.
TOXICON (2009)
Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A
Moshe Jakubowski et al.
PAIN (2006)
Duration of migraine is a predictor for response to botulinum toxin type A
EJ Eross et al.
HEADACHE (2005)
The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version
D D'Amico et al.
CEPHALALGIA (2001)
Share Paper
